@NutritionMadeS3 @theproof @DrNadolsky @DrKarlNadolsky @drmatthewnagra @MichaelAlbertMD @MichaelMindrum Review Link: pubmed.ncbi.nlm.nih.gov/39778517/ I allowed myself to translate your post into French and post it on Instagram as well (quoting you of course) Join the conversation
It is also worth noting that the FDAs Adverse Event Reporting System (FAERS) has received reports of appendicitis from patients using these medications in the real world outside of controlled trials
Approximately 80% of participants achieved clinically meaningful weight loss (5% of baseline weight)
Stomach acids and digestive enzymes can destroy glutathione, limiting its effectiveness
Cycling Considerations Most protocols recommend cycling off after 12 to 16 weeks to prevent potential receptor desensitization and maintain hormonal sensitivity
At the end of 2016, the Amgen team filed a patent (US20170275370A1) titled "Methods for Treating or Ameliorating Metabolic Disorders Using a GIPR Binding Protein in Combination with a GLP-1 Agonist." This reported the therapeutic potential of using an antibody targeting the GIPR in combination with a GLP-1 receptor agonist for the treatment of type 2 diabetes, obesity, dyslipidemia, elevated levels of glucose, increased insulin levels, and diabetic nephropathy
